Venlo, The Netherlands 1/12/10—QIAGEN NV has acquired ESE GmbH, a developer and manufacturer of UV and fluorescence optical measurement devices, for $19 million in cash. ESE’s detection technology is fast, compact and can be manufactured at a low cost, according to QIAGEN, making it suitable for point-of-need testing and integration into lab instruments. The devices can measure signals generated by QIAGEN’s technology, including Helicase-Dependent Amplification (HDA)-based assays for several pathogens. “We believe it will considerably strengthen QIAGEN’s portfolio of detection technologies and help us to better address the needs of our existing customers in a range of application fields,” stated QIAGEN CEO Peer Schatz. “In addition, due to the unique features of ESE’s technology, this transaction allows QIAGEN to synergistically apply our sample and assay technologies to the exciting, emerging point-of-need testing market segment.” In 2010, the transaction is expected to contribute $6 million in sales and to be neutral to EPS. QIAGEN plans to submit its first corresponding assays for regulatory approval and to launch clinical systems after 2011. ESE’s development and manufacturing site in Stockach, Germany, will become a Center for Excellence in Detection Development and is expected to retain all employees.